Perrigo (PRGO) Stock Forecast & Price Target
$2.22B
Market Cap
-1.27
P/E
7.33
Forward P/E
57
Score
PRGO price $16.05 +0.13 +0.82%
Stocklytics score rationale: value 72, quality 44, growth 55.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 5280600000 | 4946200000 | 4731700000 | 3869900000 | 4088200000 | 4138700000 | 4451600000 | 4655600000 | 4373400000 | 4253100000 |
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte…
Consensus Buy from 6 analysts. Average price target $36.20, +125.5% versus the current price. Low $20.00. High $54.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $36.20 for Perrigo Company (PRGO), 128.2% above the current price of $15.86. Of 6 analysts covering the stock, 2 rate it Buy or Strong Buy, 4 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $20.00 |
|---|---|
| Average | $36.20 |
| High | $54.00 |
The average is 128.2% above the current price of $15.86.
Of 6 analysts, 2 rate Perrigo Company Buy or Strong Buy, 4 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Analyst averages on file: 2026, EPS $2.19, revenue $4.05 billion. 2027, EPS $2.39, revenue $4.07 billion.
The Stocklytics Score for PRGO is 57 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
$36.20 average, with a published range of $20.00 to $54.00.
The consensus is Buy from 6 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is $2.19. The average revenue estimate is $4.05 billion.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: Perrigo Company · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$2.22B
Market Cap
-1.27
P/E
7.33
Forward P/E
57
Score